~~<i id='387B8DFAD8'><strike id='387B8DFAD8'><tt id='387B8DFAD8'><pre id='387B8DFAD8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

leisure time

author：focus 2025-09-28 18:30:54 - browse：675

Adam's take main illustration — Molly Ferguson/STAT

I was wrong about Geron.

For years, I’ve believed — and declared publicly — that Geron’s effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved, I said.

On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat’s favor, concluding the drug’s benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome. The strong endorsement makes an FDA approval highly likely. The decision is expected on or before June 16.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Listen: More tumult at BIO & coercive care for sickle cell patients

hotspot

Wikipedia

leisure time

hotspot

explore

AdobeTheFoodandDrugAdministrationispoisedtotelldrugandmedicaldevicemakershowtobetterincludepeopleofc

WSS

A public health expert passes on football's full body collisions for youths

Millions may soon lose Medicaid when they don't have to

Timeline: Key moments in fight for gay rights

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Can medical device makers keep up in the race to treat obesity?

Can medical device makers keep up in the race to treat obesity?

explore

leisure time

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Bird flu surveillance in wastewater gets boost from consortium

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Guidelines to prevent youth baseball injuries need more muscle

FDA approves first new drug developed for postpartum depression

23andMe had bad news about my health. I wish a person had delivered it

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

BioMarin wins approval for gene therapy to treat hemophilia A

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

hotspot

Bispecific antibodies are next new thing in cancer immunotherapy

Altering the blood type of lungs raises potential for universal organs for transplants

Millions may soon lose Medicaid when they don't have to

Addressing health care workers' trauma can help fight burnout

Eli Lilly’s Mounjaro succeeds in second weight

Reports of telehealth's death have been greatly exaggerated

Wikipedia

leisure time

hotspot

explore